Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia. 2015

Maria Kyrgiou, and Anita Mitra, and Marc Arbyn, and Maria Paraskevaidi, and Antonios Athanasiou, and Pierre P L Martin-Hirsch, and Phillip Bennett, and Evangelos Paraskevaidis
Surgery and Cancer - West London Gynaecological Cancer Center, Imperial College - Queen Charlotte's & Chelsea, Hammersmith Hospital, Imperial NHS Healthcare Trust, Du Cane Road, London, UK, W12 0HS.

BACKGROUND Cervical intra-epithelial neoplasia (CIN) typically occurs in young women of reproductive age. Although several studies have reported the impact that cervical conservative treatment may have on obstetric outcomes, there is much less evidence for fertility and early pregnancy outcomes. OBJECTIVE To assess the effect of cervical treatment for CIN (excisional or ablative) on fertility and early pregnancy outcomes. METHODS We searched in January 2015 the following databases: the Cochrane Gynaecological Cancer Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library, Issue 12, 2014), MEDLINE (up to November week 3, 2014) and EMBASE (up to week 52, 2014). METHODS We included all studies reporting on fertility and early pregnancy outcomes (less than 24 weeks of gestation) in women with a history of CIN treatment (excisional or ablative) as compared to women that had not received treatment. METHODS Studies were classified according to the treatment method used and the fertility or early pregnancy endpoint. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated using a random-effects model and inter-study heterogeneity was assessed with I(2). Two review authors (MK, AM) independently assessed the eligibility of retrieved papers and risk of bias. The two review authors then compared their results and any disagreements were resolved by discussion. If still unresolved, a third review author (MA) was involved until consensus was reached. RESULTS Fifteen studies (2,223,592 participants - 25,008 treated and 2,198,584 untreated) that fulfilled the inclusion criteria for this review were identified from the literature search. The meta-analysis demonstrated that treatment for CIN did not adversely affect the chances of conception. The overall pregnancy rate was higher for treated (43%) versus untreated women (38%; RR 1.29, 95% CI 1.02 to 1.64; 4 studies, 38,050 participants, very low quality), although the inter-study heterogeneity was considerable (P < 0.01). The pregnancy rates in treated and untreated women with an intention to conceive (88% versus 95%, RR 0.93, 95% CI 0.80 to 1.08; 2 studies, 70 participants, very low quality) and the number of women requiring more than 12 months to conceive (14% versus 9%, RR 1.45, 95% CI 0.89 to 2.37; 3 studies, 1348 participants, very low quality) were no different. Although the total miscarriage rate (4.6% versus 2.8%, RR 1.04, 95% CI 0.90 to 1.21; 10 studies, 39,504 participants, low quality) and first trimester miscarriage rate (9.8% versus 8.4%, RR 1.16, 95% CI 0.80 to 1.69, 4 studies, 1103 participants, low quality) was similar for treated and untreated women, CIN treatment was associated with an increased risk of second trimester miscarriage, (1.6% versus 0.4%, RR 2.60, 95% CI 1.45 to 4.67; 8 studies, 2,182,268 participants, low quality). The number of ectopic pregnancies (1.6% versus 0.8%, RR 1.89, 95% CI 1.50 to 2.39; 6 studies, 38,193 participants, low quality) and terminations (12.2% versus 7.4%, RR 1.71, 95% CI 1.31 to 2.22; 7 studies, 38,208 participants, low quality) were also higher in treated women.The results should be interpreted with caution. The included studies were often small with heterogenous design. Most of these studies were retrospective and of low or very low quality (GRADE assessment) and were therefore prone to bias. Subgroup analyses for the individual treatment methods and comparison groups and analysis to stratify for the cone length was not possible. CONCLUSIONS This meta-analysis suggests that treatment for CIN does not adversely affect fertility, although treatment was associated with an increased risk of miscarriage in the second trimester. These results should be interpreted with caution as the included studies were non-randomised and many were of low or very low quality and therefore at high risk of bias. Research should explore mechanisms that may explain the increase in mid-trimester miscarriage risk and stratify this impact of treatment by the length of the cone and the treatment method used.

UI MeSH Term Description Entries
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011256 Pregnancy Outcome Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; or SPONTANEOUS ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO. Outcome, Pregnancy,Outcomes, Pregnancy,Pregnancy Outcomes
D002578 Uterine Cervical Dysplasia Abnormal development of immature squamous EPITHELIAL CELLS of the UTERINE CERVIX, a term used to describe premalignant cytological changes in the cervical EPITHELIUM. These atypical cells do not penetrate the epithelial BASEMENT MEMBRANE. Cervical Dysplasia,Cervical Intraepithelial Neoplasia,Cervix Dysplasia,Dysplasia of Cervix Uteri,Neoplasia, Cervical Intraepithelial,Cervical Intraepithelial Neoplasia, Grade III,Cervical Intraepithelial Neoplasms,Intraepithelial Neoplasia, Cervical,Cervical Dysplasia, Uterine,Cervical Dysplasias,Cervical Intraepithelial Neoplasm,Cervix Uteri Dysplasia,Cervix Uteri Dysplasias,Dysplasia, Cervical,Dysplasia, Cervix,Dysplasia, Uterine Cervical,Intraepithelial Neoplasm, Cervical,Intraepithelial Neoplasms, Cervical,Neoplasm, Cervical Intraepithelial,Neoplasms, Cervical Intraepithelial
D005260 Female Females
D005298 Fertility The capacity to conceive or to induce conception. It may refer to either the male or female. Fecundity,Below Replacement Fertility,Differential Fertility,Fecundability,Fertility Determinants,Fertility Incentives,Fertility Preferences,Fertility, Below Replacement,Marital Fertility,Natural Fertility,Subfecundity,World Fertility Survey,Determinant, Fertility,Determinants, Fertility,Fertility Determinant,Fertility Incentive,Fertility Preference,Fertility Survey, World,Fertility Surveys, World,Fertility, Differential,Fertility, Marital,Fertility, Natural,Preference, Fertility,Preferences, Fertility,Survey, World Fertility,Surveys, World Fertility,World Fertility Surveys
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000022 Abortion, Spontaneous Expulsion of the product of FERTILIZATION before completing the term of GESTATION and without deliberate interference. Abortion, Tubal,Early Pregnancy Loss,Miscarriage,Spontaneous Abortion,Abortions, Spontaneous,Abortions, Tubal,Early Pregnancy Losses,Loss, Early Pregnancy,Losses, Early Pregnancy,Miscarriages,Pregnancy Loss, Early,Pregnancy Losses, Early,Spontaneous Abortions,Tubal Abortion,Tubal Abortions
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D018873 Pregnancy Rate The ratio of the number of conceptions (CONCEPTION) including LIVE BIRTH; STILLBIRTH; and fetal losses, to the mean number of females of reproductive age in a population during a set time period. Live-Birth Pregnancy Rate,Pregnancy Rate, Live-Birth,Pregnancy Rates,Rate, Pregnancy,Rates, Pregnancy,Live Birth Pregnancy Rate,Live-Birth Pregnancy Rates,Pregnancy Rate, Live Birth,Pregnancy Rates, Live-Birth,Rate, Live-Birth Pregnancy,Rates, Live-Birth Pregnancy

Related Publications

Maria Kyrgiou, and Anita Mitra, and Marc Arbyn, and Maria Paraskevaidi, and Antonios Athanasiou, and Pierre P L Martin-Hirsch, and Phillip Bennett, and Evangelos Paraskevaidis
October 1998, Journal of lower genital tract disease,
Maria Kyrgiou, and Anita Mitra, and Marc Arbyn, and Maria Paraskevaidi, and Antonios Athanasiou, and Pierre P L Martin-Hirsch, and Phillip Bennett, and Evangelos Paraskevaidis
April 2015, Evidence-based medicine,
Maria Kyrgiou, and Anita Mitra, and Marc Arbyn, and Maria Paraskevaidi, and Antonios Athanasiou, and Pierre P L Martin-Hirsch, and Phillip Bennett, and Evangelos Paraskevaidis
January 1991, BMJ (Clinical research ed.),
Maria Kyrgiou, and Anita Mitra, and Marc Arbyn, and Maria Paraskevaidi, and Antonios Athanasiou, and Pierre P L Martin-Hirsch, and Phillip Bennett, and Evangelos Paraskevaidis
September 2008, BMJ (Clinical research ed.),
Maria Kyrgiou, and Anita Mitra, and Marc Arbyn, and Maria Paraskevaidi, and Antonios Athanasiou, and Pierre P L Martin-Hirsch, and Phillip Bennett, and Evangelos Paraskevaidis
December 2016, Obstetrics and gynecology,
Maria Kyrgiou, and Anita Mitra, and Marc Arbyn, and Maria Paraskevaidi, and Antonios Athanasiou, and Pierre P L Martin-Hirsch, and Phillip Bennett, and Evangelos Paraskevaidis
December 1990, BMJ (Clinical research ed.),
Maria Kyrgiou, and Anita Mitra, and Marc Arbyn, and Maria Paraskevaidi, and Antonios Athanasiou, and Pierre P L Martin-Hirsch, and Phillip Bennett, and Evangelos Paraskevaidis
October 2009, Obstetrics and gynecology,
Maria Kyrgiou, and Anita Mitra, and Marc Arbyn, and Maria Paraskevaidi, and Antonios Athanasiou, and Pierre P L Martin-Hirsch, and Phillip Bennett, and Evangelos Paraskevaidis
July 1991, Gynecologic oncology,
Maria Kyrgiou, and Anita Mitra, and Marc Arbyn, and Maria Paraskevaidi, and Antonios Athanasiou, and Pierre P L Martin-Hirsch, and Phillip Bennett, and Evangelos Paraskevaidis
May 2013, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Maria Kyrgiou, and Anita Mitra, and Marc Arbyn, and Maria Paraskevaidi, and Antonios Athanasiou, and Pierre P L Martin-Hirsch, and Phillip Bennett, and Evangelos Paraskevaidis
April 1997, Lancet (London, England),
Copied contents to your clipboard!